ArticleBMC infectious diseases2026
A validated prediction model for intestinal vancomycin-resistant Enterococcus colonization in critically ill patients with sepsis: insights into risk stratification and clinical impact.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundIntestinal colonization with vancomycin-resistant Enterococcus (VRE) is a critical precursor to invasive infection. However, data on its determinants and prognostic implications in critically ill patients with sepsis remain limited. This study aimed to develop and internally validate a prediction model for intestinal VRE colonization and to assess its clinical consequences.
methodsWe conducted a retrospective cohort study of adult patients with sepsis admitted to the intensive care unit (ICU) of a tertiary medical center in Taiwan in 2024. Multivariable logistic regression was used to identify independent predictors of intestinal VRE colonization, and two prediction models were developed and internally validated using a split-sample approach. Model performance was assessed by discrimination, calibration, and decision curve analysis. The incidences of VRE-related urinary tract infection and bacteremia within 30 days of ICU admission were compared between colonized and non-colonized patients.
resultsAmong 250 eligible patients, 14.0% had intestinal VRE colonization. Three independent predictors were identified: the Charlson Comorbidity Index (adjusted odds ratio [aOR], 1.676; 95% confidence interval [CI], 1.268-2.214), prior exposure to cephalosporins (aOR, 2.80; 95% CI, 1.146-6.841), and enteral feeding (aOR, 5.21; 95% CI, 1.16-23.41). The final model showed good discrimination, with an AUC of 0.751 (95% CI, 0.572-0.930) in the validation cohort. Calibration analyses indicated good agreement between predicted and observed risks, and decision curve analysis showed positive net benefit across clinically relevant threshold probabilities. Patients with baseline VRE colonization had significantly higher risks of subsequent VRE-related urinary tract infection (22.9% vs. 1.4%, p < 0.001) and bacteremia (5.7% vs. 0.5%, p = 0.008).
conclusionsWe developed and internally validated a prediction model with potential clinical utility for early risk stratification in critically ill patients with sepsis. CLINICAL
trial registrationClinical trial number: not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.